Objective: The primary target of this study is to explore a novel therapeutic pathway of nano diosgenin by pinpointing the metabolic enzymes that underlies nano diosgenin's anti- breast cancer impacts. Methods: A single dosage of 7,12 Dimethyl Benz(a)anthracene (DMBA) (25 mg/kg b.wt) was injected to induce breast cancer. Oral administration of Diosgenin (DG) (10 mg/kg b.wt) and Diosgenin encapsulated chitosan nanoparticle (DG@CS-NP) (5 mg/kg b.wt) was used to medicate DMBA-induced tumour-bearing rats just after the emergence of a tumour. After the experimental period, biochemical analyses were carried out. Results: Mammary carcinoma-bearing rats showed a significant rise in the levels of glycolytic enzymes (hexokinase, phosphoglucoisomerase, aldolase) and the pentose phosphate pathway enzyme (glucose-6-phosphate dehydrogenase). It also elicits a drop in gluconeogenic enzymes (glucose-6-phosphatase and fructose 1, 6- diphosphatase) and mitochondrial enzymes (succinate dehydrogenase and malate dehydrogenase). Contrarily, nano diosgenin dramatically reverted the rates of glycolytic enzymes, pentose phosphate pathway enzymes, gluconeogenic enzymes, and mitochondrial enzymes in the mammary, liver and kidney tissues to near normal tiers on compared to plain diosgenin treated rats. Thereby, confirming its chemotherapeutic prospects on metabolic rewiring. Conclusion: Thus, our observations suggested that nano diosgenin is a potent therapeutic agent that might have a significant influence on metabolic complications of breast cancer than plain diosgenin. Keywords: Nano diosgenin , Mammary carcinoma , Carbohydrate metabolizing enzymes
Corresponding Author: Mirunalini Sankaran